LIMN — Liminatus Pharma Income Statement
0.000.00%
Last trade - 00:00- $22.97m
- $23.69m
Annual income statement for Liminatus Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Total Operating Expenses | 4 | 2.71 | 4.82 | 3.33 |
| Operating Profit | -4 | -2.71 | -4.82 | -3.33 |
| Total Net Non Operating Interest Income / Expense | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Net Income Before Taxes | -5.61 | -2.93 | -4.98 | -3.55 |
| Net Income After Taxes | -5.61 | -2.93 | -4.98 | -3.55 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -5.61 | -2.93 | -4.98 | -3.55 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -5.61 | -2.93 | -4.98 | -3.55 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.216 | -0.113 | -0.192 | -0.136 |